Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Shizuko Muraoka"'
Publikováno v:
Frontiers in Behavioral Neuroscience, Vol 13 (2019)
In patients with Parkinson’s disease (PD), non-motor symptoms (NMS) including depression and anxiety are often recognized before motor symptoms develop. Monoamine oxidase (MAO)-B inhibitors are therapeutically effective for motor symptoms; however,
Externí odkaz:
https://doaj.org/article/4390525d012e4dcb99dba3ad4bc406fc
Autor:
Kazue Takahata, Hiroshi Katsuki, Toshiaki Kume, Ken Ito, Yoshinaga Tochikawa, Shizuko Muraoka, Fumio Yoneda, Satoshi Kashii, Yoshihito Honda, Akinori Akaike
Publikováno v:
Journal of Pharmacological Sciences, Vol 92, Iss 4, Pp 428-432 (2003)
We compared the degree of neurotoxic outcome in the retina exposed to three nitric oxide (NO) donors with different half-life of NO release. Intravitreal injection of NO donors resulted in a significant decrease in cell density in the ganglion cell l
Externí odkaz:
https://doaj.org/article/88464cee5328490ea9f8e3f975bbcf84
Publikováno v:
European journal of pharmacology. 895
Fabry disease (FD) is an X-linked metabolic storage disorder arising from the deficiency of lysosomal α-galactosidase A, which leads to the gradual accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), throughout the body. Pain in
Autor:
Hiroshi Satoyoshi, Naoya Hoshino, Shizuko Muraoka, Kazue Takahata, Motoki Okano, Tetsuya Nishimura, Hiroko Tsunekawa, Toshiko Ishikawa
Publikováno v:
Behavioural Brain Research. 347:350-359
3,4-Dihydroxy- l -phenylalanine ( l -Dopa) remains the most effective drug for treating the motor symptoms of Parkinson’s disease (PD). However, its long-term use is limited due to motor complications such as wearing-off and dyskinesia. A clinical
Publikováno v:
Journal of Neural Transmission
l-Methamphetamine has been occasionally referred to as a stimulant similar to d-methamphetamine, probably owing to insufficient comparative studies. Here, we directly compared psychomotor efficacies and pharmacokinetics of methamphetamine enantiomers
Publikováno v:
Frontiers in Behavioral Neuroscience, Vol 13 (2019)
Frontiers in Behavioral Neuroscience
Frontiers in Behavioral Neuroscience
In patients with Parkinson's disease (PD), non-motor symptoms (NMS) including depression and anxiety are often recognized before motor symptoms develop. Monoamine oxidase (MAO)-B inhibitors are therapeutically effective for motor symptoms; however, t
Publikováno v:
European Journal of Pharmacology. 895:173882
Fabry disease (FD) is an X-linked metabolic storage disorder arising from the deficiency of lysosomal α-galactosidase A, which leads to the gradual accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), throughout the body. Pain in
Publikováno v:
European Journal of Pharmacology. 868:172793
In memoriam of Joseph Knoll: the selegiline story continues.
Autor:
Toshiko Ishikawa, Akiko Minami, Shizuko Muraoka, Motoki Okano, Kazue Takahata, Hiroshi Satoyoshi, Hiroko Tsunekawa, Yuka Tsukamoto
Publikováno v:
Behavioural brain research. 359
Selegiline, an irreversible inhibitor of monoamine oxidase (MAO)-type B, is widely prescribed for Parkinson’s disease and, at higher doses, for major and atypical depression, whereby it is non-selectively inhibitory to both MAO-A and MAO-B activiti
Publikováno v:
Arzneimittelforschung. 49:72-79
A new phthalimido compound, N-[2-(2-phthalimidoethoxy)acetyl]-L-alanyl-D-glutamic acid (CAS 142489-47-2, LK423), was examined along with other N-acyl-desmuramyldipeptide compounds for possible immunomodulating activities in cyclophosphamide (Cy)-trea